肿瘤特异性抗原和免疫佐剂在癌症免疫治疗中的应用。
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
机构信息
de Duve Institute, University of Louvain, Brussels, Belgium.
出版信息
Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004.
PMID:21952282
Abstract
T cell-based cancer immunotherapy relies on advancements made over the last 20 years on the molecular mechanisms underlying the antigenicity of tumors. This review focuses on human tumor antigens recognized by T lymphocytes, particularly the reasons why some are tumor-specific but others are not, and on the immunologic adjuvants used in clinical trials on therapeutic vaccination with defined tumor antigens.
摘要
基于 T 细胞的癌症免疫疗法依赖于过去 20 年来在肿瘤抗原性的分子机制方面取得的进展。本文重点介绍了被 T 淋巴细胞识别的人类肿瘤抗原，特别是某些抗原具有肿瘤特异性而另一些没有的原因，以及在使用定义明确的肿瘤抗原进行治疗性疫苗接种的临床试验中使用的免疫佐剂。
Zotero 插件